Equity (Tables)

12 Months Ended

Dec. 31, 2020

Equity [Abstract]

Schedule of Convertible Preferred Shares

As of December 31, 2020, the Number of Preferred shares the amount each class is convertible into is below:  

	Number of Preferred Stock		Number of underlying Common stock
Series B Convertible Preferred Stock*		17,303		3,112,923	**
Series C Convertible Preferred Stock		2,343		46,714	***
Total				3,159,637

* See “Note 11 - Subsequent events” regarding conversion of all remaining Series B Convertible Preferred Stock into common stock.

** On July 7, 2016, we issued 442,424 shares of Series B Preferred Stock in a public offering. Our Series B Preferred Stock has a stated value of $33.00 which currently converted into 3,112,923 reflecting a conversion price equal to $ 0.321. The holders of Series B Preferred Stock are entitled to receive as cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company’s discretion, but excluding effect of future conversion price adjustment, if any.

*** On March 14, 2017, we issued 1,069,822 shares of Series C Preferred Stock in a public offering. Our Series C Preferred Stock has a stated value of $6.40 which currently converted into 46,714 reflecting a conversion price equal to $ 0.321.

Schedule of Issuance of Warrants to Purchase Common Stock

As of December 31, 2020, the Company has outstanding warrants to purchase an aggregate of 26,705,502 shares of common stock as follows:

	Number of underlying Common stock		Weighted average exercise price
Series A Warrants		1,107	$	8,750.00
Series B Warrants		2,448	$	3,500.00
Series D Warrants		766,698	$	15.00
Series E Warrants		2,972,221	$	1.80
Series F Warrants		22,688,900	$	0.50
Underwriter Warrants		274,029	$	0.50
Other warrants		99	$	21,993.00
Total Warrants		26,705,502	$	1.82

Schedule of Stock Options Granted

5) The following table summarizes information about stock options granted to employees:

	Year ended December 31
	2020					2019
	Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
Outstanding - beginning of period		160		$	189,161.99		164		$	184,656
Granted		1,379,856			0.41		-			-
Forfeited		(4,751	)		343.51		(4	)		4,423
Outstanding -end of period		1,375,265		$	21.24		160		$	189,162
Exercisable at the end of the period		115		$	249,006		160		$	189,162

6) The following table summarizes information about stock options granted to non-employees:

	Year ended December 31
	2020					2019
	Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
Outstanding - beginning of period		16		$	1,711,975		20		$	1,693,174
Granted		-			-		-			-
Forfeited		(1	)		2,156,208		(4	)		1,617,338
Exercised		-			-		-			-
Outstanding - end of period		15			1,682,385		16			1,711,975
Exercisable at the end of the period		15			1,682,385		16			1,711,975

Schedule of Restricted Stock Granted to Employees

7) The following table summarizes information about restricted stock granted to employees:

	Year ended December 31
	2020			2019
	Number of restricted stock
Outstanding - beginning of period		69,631			19
Reverse Split Adjustments		-			(127	)
Granted		2,781,920			70,582
Forfeited		(55,755	)		(838	)
Vested		(9,915	)		(5	)
Outstanding - end of period		2,785,881			69,631

Schedule of Restricted Stock Unit Granted to Employees

8) The following table summarizes information about Restricted Stock Unit granted to employees:

	Year ended December 31
	2020			2019
	Number of restricted stock
Outstanding - beginning of period		165,000			-
Granted		1,357,668			165,000
Forfeited		-			-
Vested		(165,000	)		-
Outstanding - end of period		1,357,668			165,000

Schedule of Additional Information About All Options Outstanding and Exercisable

9) The following table provides additional information about all options outstanding and exercisable:

	Outstanding as of December 31, 2020
Exercise price	Options outstanding		Weighted average remaining contractual life (years)		Options exercisable
$0.175		2		1.39		2
$0.33-0.39		1,314,356		9.69		-
$1.10		60,794		9.01		-
$175 and above		128		4.71		128
		1,375,280		9.66		130

Schedule of Fair Value of Options Granted to Employees

10) The following table sets forth the assumptions that were used in determining the fair value of options granted to employees for the year December 31, 2020:

	Year ended December 31
	2020
Expected life		5.5-6.5 years
Risk-free interest rates		0.32%-0.42	%
Volatility		124.53%-136.66	%
Dividend yield		0	%

Schedule of Allocation of Total Share-based Compensation Expense

12) The following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations:

	Year ended December 31
	2020		2019
	($ in thousands)
Cost of revenues	$	22	$	14
Research and development		29		10
Sales and marketing		32		29
General and administrative		523		272
	$	606	$	325